Thursday, November 14, 2019 3:30:16 PM
A very well thought out post Dan,
In that I wasn't here when the trial halted, out of curiosity and from a standpoint of understanding the data, how long was it halted for, and when it was resumed, how long did it take to dose the last 31 patients, as I understand it, in the trial.
If the halt was for 6 months, and it took 6 months until the last patient entered the trial, it would mean that as of now, for the 300 who entered the trial prior to the halt, the last to be dosed there would now be 5 years beyond the initiation of treatment. I'm not saying these are the numbers, I'm asking what they should be, but the point I'm making is that with the exception of those who entered after the halt, most if not all are now survivors for roughly 5 years or more.
I suspect when we see the K-M, the big tail people speak about will really be impressive, and perhaps may extend out a decade or more is some of the earliest people to enter the trial are living or recently passed.
Gary
In that I wasn't here when the trial halted, out of curiosity and from a standpoint of understanding the data, how long was it halted for, and when it was resumed, how long did it take to dose the last 31 patients, as I understand it, in the trial.
If the halt was for 6 months, and it took 6 months until the last patient entered the trial, it would mean that as of now, for the 300 who entered the trial prior to the halt, the last to be dosed there would now be 5 years beyond the initiation of treatment. I'm not saying these are the numbers, I'm asking what they should be, but the point I'm making is that with the exception of those who entered after the halt, most if not all are now survivors for roughly 5 years or more.
I suspect when we see the K-M, the big tail people speak about will really be impressive, and perhaps may extend out a decade or more is some of the earliest people to enter the trial are living or recently passed.
Gary
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
